ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 173 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $778,000 | +31.6% | 10,400 | 0.0% | 0.52% | +18.2% |
| Q3 2021 | $591,000 | +29.0% | 10,400 | 0.0% | 0.44% | +23.7% |
| Q2 2021 | $458,000 | +106.3% | 10,400 | +131.1% | 0.36% | +95.1% |
| Q1 2021 | $222,000 | +7.8% | 4,500 | 0.0% | 0.18% | -4.2% |
| Q3 2020 | $206,000 | -8.8% | 4,500 | 0.0% | 0.19% | -5.0% |
| Q2 2020 | $226,000 | -2.2% | 4,500 | 0.0% | 0.20% | -13.7% |
| Q1 2020 | $231,000 | -54.6% | 4,500 | -25.4% | 0.23% | +21.9% |
| Q2 2019 | $509,000 | -11.6% | 6,034 | 0.0% | 0.19% | +3.2% |
| Q1 2019 | $576,000 | +34.9% | 6,034 | 0.0% | 0.19% | +31.0% |
| Q4 2018 | $427,000 | -12.0% | 6,034 | +6.3% | 0.14% | 0.0% |
| Q3 2018 | $485,000 | -19.4% | 5,676 | +9.2% | 0.14% | -18.9% |
| Q2 2018 | $602,000 | – | 5,197 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
| Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
| ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
| Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
| Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
| Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
| Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
| Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |